Loading...

ALNA - Allena Pharmaceuticals, Inc.

Top Stock Signal for 05-13-2022
Loading Chart ALNA

Stock Signal Information


Signal

Penny Stock Signal: ALNA
Report Date: 05-13-2022
Company: Allena Pharmaceuticals, Inc. (ALNA)
Sector: Healthcare
Industry: Biotechnology

ALNA Technical Analysis

Company Contact

Allena Pharmaceuticals, Inc. (ALNA)
1 Newton Executive Park Ste 202
Newton, MASSACHUSETTS 02462
Phone: 16174674577
Website: http://www.allenapharma.com
CEO: Dr. Louis Brenner

ALNA, Allena Pharmaceuticals, Inc.

ALNA Allena Pharmaceuticals, Inc. Logo Image

NASDAQ, Nasdaq Global Select

Company Profile

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Newton, Massachusetts and currently employs 45 full-time employees. The firm is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

Top Stock Signals

free stock signals, best stock trading signals, stock market signals

About Top Stock Signals

Good stock signals have been found on this server. That is all we know.

Phone: +1 (407) 559-7228
Email: [email protected]

About Us | Newsletter | Members

Most Active
Top Gainers
Top Losers